Видео ютуба по тегу 17P Deletion

Paul Barr, MD: Principle Treatment Options for Patients With a 17p Deletion
Paul Barr, MD: Principle Treatment Options for Patients With a 17p Deletion
Deletion 17p in Myeloma: Key Facts You Should Know - del (17p)
Deletion 17p in Myeloma: Key Facts You Should Know - del (17p)
Why is 17p deletion (17p-) considered to be a poor prognostic factor for myeloma patients?
Why is 17p deletion (17p-) considered to be a poor prognostic factor for myeloma patients?
TP53 and Deletion 17p as Prognostic Factors in CLL
TP53 and Deletion 17p as Prognostic Factors in CLL
Treatment options for the young CLL patient with deletion 17p: Do they need a different approach?
Treatment options for the young CLL patient with deletion 17p: Do they need a different approach?
Case 2: Newly Diagnosed CLL; Del(17p)
Case 2: Newly Diagnosed CLL; Del(17p)
Ibrutinib for CLL with Deletion 17p
Ibrutinib for CLL with Deletion 17p
Case 3: Treatment for Relapsed Myeloma with 17p Deletion
Case 3: Treatment for Relapsed Myeloma with 17p Deletion
CLL: Optimal approaches for patients with deletion 17p
CLL: Optimal approaches for patients with deletion 17p
Dr. Wierda on Treating CLL with 17p Deletion
Dr. Wierda on Treating CLL with 17p Deletion
Zanubrutinib Combined with Venetoclax for CLL Patients with Deletion 17p - Dr. Constantine Tam
Zanubrutinib Combined with Venetoclax for CLL Patients with Deletion 17p - Dr. Constantine Tam
If deletion 17 p is not detected at diagnosis, can it develop later in myeloma? #myeloma
If deletion 17 p is not detected at diagnosis, can it develop later in myeloma? #myeloma
Treatment recommendations for patients with CLL with del(17p) and TP53 aberrations
Treatment recommendations for patients with CLL with del(17p) and TP53 aberrations
Complex Karyotypes and 17p-Deletions: Appropriate for Transplant?
Complex Karyotypes and 17p-Deletions: Appropriate for Transplant?
EHA 17: Best treatment for chronic lymphocytic leukaemia with 17p deletion - Prof Michael Keating
EHA 17: Best treatment for chronic lymphocytic leukaemia with 17p deletion - Prof Michael Keating
The importance of del(17p) as a prognostic factor in myeloma
The importance of del(17p) as a prognostic factor in myeloma
Defining high-risk CLL: known and emerging mutations
Defining high-risk CLL: known and emerging mutations
The impact of genetic abnormalities on treatment decisions in CLL
The impact of genetic abnormalities on treatment decisions in CLL
Efficacy of ibrutinib in the treatment of CLL patients with del(17p) and TP53 mutation
Efficacy of ibrutinib in the treatment of CLL patients with del(17p) and TP53 mutation
Myeloma transplantation: 17p deletions & 4;14 translocations
Myeloma transplantation: 17p deletions & 4;14 translocations
Key prognostic markers in CLL: TP53, del(17p), and high complexity karyotype
Key prognostic markers in CLL: TP53, del(17p), and high complexity karyotype
CLL Prognosis and Treatment Options
CLL Prognosis and Treatment Options
The impact of gene mutations on prognosis in CLL
The impact of gene mutations on prognosis in CLL
Case 2: 17p-Deleted CLL Progressing on Ibrutinib Therapy
Case 2: 17p-Deleted CLL Progressing on Ibrutinib Therapy
Chronic Lymphocytic Leukaemia (CLL) Understanding 17p Deletion and Your Path to Treatment
Chronic Lymphocytic Leukaemia (CLL) Understanding 17p Deletion and Your Path to Treatment